Recent advances in liposomes and peptide-based therapeutics for glioblastoma treatment

J Control Release. 2024 Dec:376:732-752. doi: 10.1016/j.jconrel.2024.10.037. Epub 2024 Oct 30.

Abstract

In the context of glioblastoma treatment, the penetration of drugs is drastically limited by the blood-brain-barrier (BBB). Emerging therapies have focused on the field of therapeutic peptides for their excellent BBB targeting properties that promote a deep tumor penetration. Peptide-based strategies are also renowned for their abilities of driving cargo such as liposomal system allowing an active targeting of receptors overexpressed on GBM cells. This review provides a detailed description of the internalization mechanisms of specific GBM homing and penetrating peptides as well as the latest in vitro/in vivo studies of liposomes functionalized with them. The purpose of this review is to summarize a selection of promising pre-clinical results that demonstrate the advantages of this nanosystem, including an increase of tumor cell targeting, triggering drug accumulation and thus a strong antitumor effect. Aware of the early stage of these studies, many challenges need to be overcome to promote peptide-directed liposome at clinical level. In particular, the lack of suitable production, the difficulty to characterize the nanosystem and therapeutic competition leaded by antibodies.

Keywords: Cell penetration peptide; Glioblastoma; Liposomes; Targeting; Tumor homing peptide; Uptake mechanisms.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents* / administration & dosage
  • Antineoplastic Agents* / therapeutic use
  • Blood-Brain Barrier / metabolism
  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / metabolism
  • Drug Delivery Systems
  • Glioblastoma* / drug therapy
  • Humans
  • Liposomes*
  • Peptides* / administration & dosage
  • Peptides* / chemistry
  • Peptides* / therapeutic use

Substances

  • Liposomes
  • Peptides
  • Antineoplastic Agents